Article
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
29 Dec 2011
Abstract excerpt
The tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but primary and acquired resistance of CML cells to the drug offset its efficacy. Molecular mechanisms for resistance of CML to tyrosine kinase inhibitors are not fully understood. In the present study, we show that BCR-ABL activates the expression of the mammalian stress response gene SIRT1 in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
